Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
09/02/2021 - 08:00 AM
CAMBRIDGE, Mass. Sept. 2, 2021 Kate Haviland , Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET .
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe , and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com Twitter LinkedIn
https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference-301366780.html
SOURCE Blueprint Medicines Corporation
BPMC Rankings
#1628 Ranked by Stock Gains
BPMC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About BPMC
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
